Media Search:



Characterization of PANoptosis-related genes in Crohn’s disease by integrated bioinformatics, machine learning and … – Nature.com

GEO dataset integration and immune landscape of CD

We constructed a combined dataset covering 279 CD samples and 224 control samples from mucosa after the removal of batch effects (Fig.2A,B). A broadly uncoordinated immune response is an indispensable hallmark of CD. With the aim of revealing the immune landscape, we scored the immune cell infiltration of CD patients and controls via the ssGSEA method. As illustrated in Fig.2C, the infiltration of 20 immune cells in the CD group and control group was significantly different, among which only the scores of T helper 17 (Th17) cells were lower in CD tissues than in control tissues. We then performed a correlation analysis of distinct immune cells, as shown in Fig.2D. Interestingly, Th17 cells, CD56bright natural killer (NK) cells, CD56dim NK cells and monocytes showed inverse correlations with almost all other immune cells, whereas the other immune cells were generally positively correlated with one another, which deserves special attention.

GEO dataset combination and immune landscape of CD. (A) PCA between datasets before removal of batch effects. (B) PCA between integrated datasets after removal of batch effects. (C) Infiltration levels of 28 immune cell subtypes in CD samples and controls. The blue bars represent controls, and the red bars represent CD samples. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. (D) Pearson correlation analysis of distinct immune cells. The purple squares represent positive correlations, and the orange squares represent inverse correlations. GEO Gene Expression Omnibus, CD Crohns disease, PCA principal component analysis.

A total of 1265 DEGs, consisting of 592 upregulated and 673 downregulated genes, were identified through differential expression analysis (Fig.3A). A list of possible PRGs was produced from previous research (Supplementary file 1: Table S1). Subsequently, we intersected the 1265 DEGs with 930 PRGs via a Venn diagram; thus, 130 DE-PRGs were identified (Fig.3B), which were further grouped in a heatmap (Fig.3C). The overall expression of these DE-PRGs in the CD group and control group is shown in Supplementary file 3: Fig. S1. We could conclude that the vast majority of DE-PRGs were expressed at higher levels in CD tissues than in control tissues.

Identification of DE-PRGs. (A) Volcano map of the DEGs with the cutoff threshold set at |log2 (fold change)|>1 and adj. p<0.05. The blue dots represent downregulated DEGs, the red dots represent upregulated DEGs, and the gray dots represent genes with no significant difference. (B) Venn diagram of DEGs and PRGs. Pink circle represents DEGs, blue circle represents PRGs, and their overlapping area represents DE-PRGs. (C) Clustered heatmap of the top 40 DE-PRGs. Each row represents one of the top 40 DE-PRGs, and each column represents one sample, either CD or normal. DE-PRGs differentially expressed PANoptosis-related genes, DEGs differentially expressed genes, PRGs PANoptosis-related genes, CD Crohns disease.

We then examined the latent functions and signaling pathways of the DE-PRGs. GO analysis revealed that these DE-PRGs were predominantly involved in regulation of apoptotic signaling pathway, leukocyte cellcell adhesion, regulation of inflammatory response (biological process); membrane raft, membrane microdomain, focal adhesion (cellular component); ubiquitin-like protein ligase binding, ubiquitin protein ligase binding, and phosphatase binding (molecular function) (Supplementary file 4: Fig. S2A). Additionally, DE-PRGs were notably enriched in apoptosis, proteoglycans in cancer, NOD-like receptor signaling pathway, among others, according to the KEGG results (Supplementary file 4: Fig. S2B). Moreover, a PPI network analysis of the DE-PRGs was performed and a complex network of the DE-PRGs was constructed (Supplementary file 5: Fig. S3).

To screen the hub DE-PRGs, we first capitalized on three algorithms, LASSO, SVM and RF, and discovered 20, 34 and 33 potential hub DE-PRGs, respectively (Fig.4AE). Afterward, 10 hub DE-PRGs were identified through the intersection of the machine learning results, namely CD44, cell death inducing DFFA like effector c (CIDEC), N-myc downstream regulated 1 (NDRG1), nuclear mitotic apparatus protein 1 (NUMA1), proliferation and apoptosis adaptor protein 15 (PEA15), recombination activating 1 (RAG1), S100 calcium binding protein A8 (S100A8), S100 calcium binding protein A9 (S100A9), TIMP metallopeptidase inhibitor 1 (TIMP1) and X-box binding protein 1 (XBP1) (Fig.4F). Next, we probed their interactions, as shown in Fig.4G. Most hub DE-PRGs, such as CD44, PEA15, S100A8, S100A9, TIMP1 and XBP1, were closely interrelated. Moreover, NDRG1, NUMA1 and RAG1 generally presented antagonistic effects on the other hub DE-PRGs. Finally, the diagnostic value of each hub DE-PRG in predicting CD was calculated based on our combined dataset (Fig.4H). All 10 hub DE-PRGs exhibited outstanding predictive performance with area under the curve (AUC) values greater than 0.740. Notably, the AUC reached as high as 0.871 when the 10 hub DE-PRGs were combined (Fig.4H). In addition, we conducted external validation on the GSE102133 and GSE207022 datasets, respectively. The results were satisfactory, with high AUC values (Supplementary file 6: Fig. S4).

Identification of the hub DE-PRGs. (A) Cross-validations of adjusted parameter selection in the LASSO model. Each curve corresponds to one gene. (B) LASSO coefficient analysis. Vertical dashed lines are plotted at the best lambda. (C) SVM algorithm for hub gene selection. (D) Relationship between the number of random forest trees and error rates. (E) Ranking of the relative importance of genes. (F) Venn diagram showing the 10 hub DE-PRGs identified by LASSO, SVM and RF. Pink circle represents potential hub DE-PRGs identified by RF, blue circle represents potential hub DE-PRGs identified by SVM, green circle represents potential hub DE-PRGs identified by LASSO, and their overlapping area represents the final hub DE-PRGs. (G) Chord diagram showing the correlations between the hub DE-PRGs. Red represents positive correlations between different genes and green represents negative correlations between different genes. (H) ROC curves of the hub DE-PRGs in CD diagnosis. DE-PRGs differentially expressed PANoptosis-related genes, LASSO least absolute shrinkage and selection operator, RF random forest, SVM support vector machine, ROC receiver operating characteristic, AUC area under the curve, CD Crohns disease.

Spearman correlation analysis was carried out to determine the interactions between the hub DE-PRGs and immune cells (Fig.5). CD44, PEA15, S100A8, S100A9, TIMP1 and XBP1 demonstrated noteworthy positive correlations with the infiltration of an abundance of immune cells, except for certain immune cells, such as monocytes and CD56bright NK cells. In contrast, NDRG1, NUMA1, and RAG1 were negatively associated with most types of immune cells, excluding a few immune cells such as monocytes. In addition, the CIDEC fell somewhere between these two extremes.

Spearman correlation analysis of hub DE-PRGs with immune cells. The correlations between CD44 (A), CIDEC (B), NDRG1 (C), NUMA1 (D), PEA15 (E), RAG1 (F), S100A8 (G), S100A9 (H), TIMP1 (I) and XBP1 (J) gene expressions with immune cells, respectively. The size of the dots represents the strength of gene correlation with immune cells; the larger the dot, the stronger the correlation. The color of the dots represents the p-value; the greener the color, the lower the p-value. p<0.05 was considered statistically significant. DE-PRGs differentially expressed PANoptosis-related genes.

The top 30 crucial genes related to CD were extracted from the GeneCards database, and their expression levels were compared between CD samples and normal samples (Fig.6A). We could easily conclude that a majority of the CD-related genes (26 out of 30) were differentially expressed, especially COL1A1, CTLA4, IL10 and NOD2. Pearson correlation analysis was subsequently conducted to scrutinize the relationships between these CD-related genes and the hub DE-PRGs (Fig.6B). Notably, CTLA4, one of the most differentially expressed CD-related genes, was significantly associated with each hub DE-PRG. COL1A1, IL10 and NOD2 also presented varying levels of correlation with the hub DE-PRGs. Nevertheless, there were no significant correlations between the hub DE-PRGs and some CD-related genes, including CYBB, IL10RA, RET and VCP.

Expression levels of the top 30 CD-related genes and relationships between them and hub DE-PRGs. (A) Boxplot of the top 30 crucial genes in relation to CD. The blue bars represent controls, and the red bars represent CD samples. (B) Pearson correlation analysis between the top 30 CD-related genes and the 10 hub DE-PRGs. *p<0.05; **p<0.01; ***p<0.001. CD Crohns disease, DE-PRGs differentially expressed PANoptosis-related genes.

Subsequently, a genemiRNA interaction network of the 10 hub DE-PRGs consisting of 226 nodes and 338 edges was constructed (Supplementary file 7: Fig. S5 and Supplementary file 8: Table S3). Apparently, miR-124-3p, miR-34a-5p and miR-27a-3p were most strongly associated with the hub DE-PRGs in CD. After that, we generated a geneTF regulatory network of the 10 hub DE-PRGs (Supplementary file 9: Fig. S6). The 10 hub DE-PRGs were regulated by 35 total TFs. Among them, FOXC1 was found to regulate as many as 7 hub DE-PRGs and S100A8 was regulated by 13 miRNAs (Supplementary file 10: Table S4). In addition, we looked for available drugs that act on the hub DE-PRGs, and a host of drugs were involved (Supplementary file 11: Fig. S7 and Supplementary file 12: Table S5). Specifically, a total of 19 drugs interacted with XBP1, 8 of which inhibited it.

To distinguish different PANoptosis patterns in CD patients, we adopted the NMF method for unsupervised clustering on the basis of the 10 hub DE-PRGs. At k=2, the most stable and optimal PANclusters were identified (Fig.7A). There were 101 and 178 CD samples in PANcluster A and PANcluster B, respectively. The geometrical distance between the two clusters is shown in Fig.7B, validating their gene expression heterogeneity. Thereafter, a boxplot and a heatmap were generated to compare the expression levels of the hub DE-PRGs between PANcluster A and PANcluster B (Fig.7C,D). Specifically, PANcluster A was distinguished by the considerably high expression levels of CIDEC, NDRG1, NUMA1 and RAG1, while the other hub DE-PRGs, that is, CD44, PEA15, S100A8, S100A9, TIMP1 and XBP1, were expressed at higher levels in PANcluster B.

Recognition of PANclusters in CD. (A) Unsupervised clustering matrix generated using NMF method when k=2. (B) PCA plot showing the distribution of PANcluster A and PANcluster B. The red dots represent PANcluster A and the blue dots represent PANcluster B. (C) Boxplot of the expression levels of the hub DE-PRGs in PANcluster A and PANcluster B. The red bars represent PANcluster A, and the blue bars represent PANcluster B. (D) Heatmap of the expression levels of the hub DE-PRGs in PANcluster A and PANcluster B. Each row represents one hub DE-PRG, and each column represents one CD sample. PANclusters PANoptosis patterns, CD Crohns disease, NMF nonnegative matrix factorization, PCA principal component analysis, DE-PRGs differentially expressed PANoptosis-related genes.

GSVA was performed with the aim of shedding light on the functional diversity patterns of the recognized PANclusters. With regard to Hallmark pathways, increased activity of p53 pathway, androgen response and hypoxia were detected in PANcluster A, whereas mTORC1 signaling, inflammatory response, TNF- signaling via NF-B, IL-6/JAK/STAT3 signaling and epithelial mesenchymal transition were increased in PANcluster B (Supplementary file 13: Fig. S8A). In addition, results from the KEGG analysis suggested that PANcluster A had hypoactive ECMreceptor interaction and endocytosis but expressed high levels of genes associated with cytokinecytokine receptor interaction and numerous signaling pathways, including toll-like receptor signaling pathway and NOD-like receptor signaling pathway (Supplementary file 13: Fig. S8B). Concerning the Reactome-based pathways, PANcluster A showed an increase in the cell cycle pathway, while most pathways, such as cytokine signaling in immune system and extracellular matrix-related pathways, were significantly enriched in PANcluster B (Supplementary file 13: Fig. S8C).

To clarify the disparities in the immune system among the PANclusters, we compared their immune microenvironments, as shown in Fig.8A. Remarkably, the enrichment scores of 26 immune cells were much greater in PANcluster B than in PANcluster A. Consequently, CD56bright NK cells and monocytes were the only two exceptions with higher infiltration degrees in PANcluster A, the explanations behind which demand further investigation. In addition, differential gene analysis revealed 533 DEGs, including 171 upregulated and 362 downregulated genes (Fig.8B). To learn more about the biological functions and processes linked to these DEGs, GO and KEGG analyses were performed. The 533 DEGs were markedly enriched in the following terms: positive regulation of cell adhesion, leukocyte cellcell adhesion, and extracellular matrix organization (biological process); collagen-containing extracellular matrix, secretory granule membrane, and basement membrane (cellular component); and extracellular matrix structural constituent, glycosaminoglycan binding, and integrin binding (molecular function) (Fig.8C,D). Moreover, the 533 DEGs were principally involved in many pathways, such as cell adhesion molecules, ECMreceptor interaction and PI3K-Akt signaling pathway (Fig.8E).

Characterization of different PANclusters. (A) Infiltration levels of 28 immune cell subtypes in PANclusters A and B. The red bars represent PANcluster A, and the blue bars represent PANcluster B. (B) Volcano map of DEGs between PANclusters A and B. The blue dots represent downregulated DEGs, the red dots represent upregulated DEGs, and the gray dots represent genes with no significant difference. (C,D) Enriched items in GO analysis based on the DEGs between PANclusters A and B. (E) Enriched items in KEGG analysis based on the DEGs between PANclusters A and B. Node color indicates gene expression level; quadrilateral color indicates z-score. PANclusters PANoptosis patterns, DEGs differentially expressed genes, BP biological process, CC cellular component, MF molecular function, GO Gene Ontology, KEGG Kyoto Encyclopedia of Genes and Genomes.

CD and control samples were acquired from 10 patients who were diagnosed with CD, and their demographic and clinical information is presented in Table 1. qRT-PCR was subsequently conducted to determine the relative expression levels of the 10 hub DE-PRGs (Fig.9A). As expected, the levels of CD44, PEA15, S100A8, S100A9, TIMP1 and XBP1 increased in CD samples compared with those in control samples; while the opposite trend was observed for NDRG1. Moreover, there was no significant difference in the mRNA expression levels of CIDEC, NUMA1 or RAG1. Furthermore, we established classic TNBS and DSS mouse models of CD and collected colon tissues to analyze the expression levels of the hub DE-PRGs in murine colon tissues from the TNBS, DSS and control groups (Fig.9B,C). Generally, the results of the TNBS model were in line with expectations. Specifically, in TNBS-induced colitis, Cd44, Numa1, S100a8, S100a9, Timp1 and Xbp1 were more highly expressed, while Cidec and Rag1 were less expressed. In addition, the levels of Ndrg1 and Pea15a did not significantly differ between the TNBS group and the control group. Consistent with previous work, in the DSS mouse model, the expression levels of Cd44, S100a8, S100a9 and Timp1 were greater in the mice with colitis; while the expression level of Ndrg1 was lower in the mice with colitis. In addition, no significant difference in the expression levels of Cidec, Pea15a or Xbp1 was detected. Unexpectedly, the expression levels of Numa1 and Rag1 in the DSS group were different from those in the CD and TNBS colitis groups.

qRT-PCR validation of the hub DE-PRGs in CD patients (A), TNBS-induced colitis model (B) and DSS-induced colitis model (C). The blue dots represent the normal/control tissues, and the red dots represent the diseased tissues. qRT-PCR quantitative real-time PCR, DE-PRGs differentially expressed PANoptosis-related genes, CD Crohns disease, TNBS 2,4,6-trinitrobenzene sulfonic acid, DSS dextran sodium sulfate, GAPDH glyceraldehyde-3-phosphate dehydrogenase.

Continued here:
Characterization of PANoptosis-related genes in Crohn's disease by integrated bioinformatics, machine learning and ... - Nature.com

Experts speak out on how high Ethereum could go with an ETF approval – Crypto Briefing

Share this article

Tomorrow is the final deadline for the approval of VanEcks spot Ethereum exchange-traded fund (ETF) in the US, and expectations are high. Bloomberg ETF analyst James Seyffart shared that an approval movement is happening, despite regulatory indicators pointing out to the contrary direction until Monday.

As a result, Ethereum (ETH) leaped up to 21% in less than 48 hours and stood just 22% from its all-time high of $4,878.26, according to data aggregator CoinGecko. Bitcoin (BTC) leaped 96% in two months before the approval of the first spot Bitcoin ETFs in the US and reached its all-time high two months later.

James Davies, co-founder and CPO at Crypto Valley Exchange, highlights that Bitcoins case was different. In that instance, though, everything came together ETFs, bitcoin halving, and global inflation easing significantly and lined up to drive Bitcoin. Ethereum has already had the crypto cycle and global market sentiment increase, he shares.

Although Davies sees Ethereum ETF inflows having a substantial impact, propelling ETH to new all-time highs, it may be hard for Ethereum to replicate BTCs movement after the funds approval. It does, however, present a great steady growth story for the rest of 2024.

Ruslan Lienkha, chief of markets at YouHodler, also shares the view that an Ethereum ETF might trigger a sharp ETH price increase. Moreover, this movement might not be fully priced, with significant upside yet to be seen. If so, it will be a powerful impetus for the whole crypto market and a stimulus for other coins growth, added Lienkha.

Bitfinexs analysts believe that a spot Ethereum ETF approval could play out just like the spot Bitcoin ETF approval, which was a sell-the-news event before a long-term bullish outlook was triggered, causing a multi-month rally. As for inflows, they expect a similar level compatible with ETHs market cap.

The current move from sub $3000 to $3800 is a result of the market pricing in the higher odds of an ETF approval. It is important that market participants often front-run and price in odds as absolute implying that 75% odds of approval by Bloomberg analysts could potentially be priced in as 100%.

Marko Jurina CEO at Jumper.Exchange, pointed out that BTC rose nearly 65% following the trading of spot Bitcoin ETFs in the US. Thus, a similar movement would propel ETH well beyond its previous all-time high. Zentner also believes that the approval might trigger a crypto market growth for the second half of 2024.

Despite the optimism regarding the Ethereum ETF approval, there is still a slight chance of rejection. Moreover, as highlighted by Seyffart, a good part of investors are misunderstanding the current movement since approval doesnt translate to immediate trading. Both of these scenarios might then upset investors.

Nevertheless, in the light of recent developments, those events are now being priced out, says James Davies, from Crypto Valley Exchange. On the other hand, Jumper.Exchanges Marko Jurina believes that both negative possible events are already priced in.

When the spot BTC ETFs first came to market, there was actually a brief sell-off where some took profits before the rally resumed. Additionally, given the volatile nature of the market, good and bad news gives ample opportunity for market makers to create more violent price swings, so blood on the streets is definitely possible. More problematic for the ETH community (if no approval) would be the loss of a narrative as a catalyst, Jurina added.

Moreover, a slight drop followed by a consolidation period is also a possibility, shares Ruslan Lienkha from YouHodler. Ethereum ETF approval is just a matter of time. The SEC will approve it sooner or later after the status clarification of ETH, and it matters little if it is recognized as a commodity, security, or something else. As for now, fundamentally, nothing will change for ETH. It will remain the second crypto in the industry even without ETFs.

Even if an unlikely rejection happens, Bitfinex analysts describe a layered scenario, which could end in a hard rejection or a soft rejection. A hard rejection would include ETH being considered a security, while a soft rejection would be limited to ETF proposals.

The former could be very bearish leading to a retrace of the entire move up currently. The latter could lead to more speculation continuing over a future approval on re-appeal, Bitfinex analysts concluded.

Share this article

The information on or accessed through this website is obtained from independent sources we believe to be accurate and reliable, but Decentral Media, Inc. makes no representation or warranty as to the timeliness, completeness, or accuracy of any information on or accessed through this website. Decentral Media, Inc. is not an investment advisor. We do not give personalized investment advice or other financial advice. The information on this website is subject to change without notice. Some or all of the information on this website may become outdated, or it may be or become incomplete or inaccurate. We may, but are not obligated to, update any outdated, incomplete, or inaccurate information.

Crypto Briefing may augment articles with AI-generated content created by Crypto Briefings own proprietary AI platform. We use AI as a tool to deliver fast, valuable and actionable information without losing the insight - and oversight - of experienced crypto natives. All AI augmented content is carefully reviewed, including for factural accuracy, by our editors and writers, and always draws from multiple primary and secondary sources when available to create our stories and articles.

You should never make an investment decision on an ICO, IEO, or other investment based on the information on this website, and you should never interpret or otherwise rely on any of the information on this website as investment advice. We strongly recommend that you consult a licensed investment advisor or other qualified financial professional if you are seeking investment advice on an ICO, IEO, or other investment. We do not accept compensation in any form for analyzing or reporting on any ICO, IEO, cryptocurrency, currency, tokenized sales, securities, or commodities.

See full terms and conditions.

Link:

Experts speak out on how high Ethereum could go with an ETF approval - Crypto Briefing

Citi discusses Ethereum ETF: Buy the rumor, sell the fact? – Investing.com

(ETH) price shot higher over the last 48 hours, driven by favorable regulatory developments that boost the chances of an ether exchange-traded fund (ETF) being approved soon.

Nevertheless, the chances of a major "buy the rumor, sell the fact" reaction for ETH seem lower compared to , according to a recent Citi report.

Bitcoin dropped 17% after ETF approval due to the hype and leveraged bets. In contrast, the potential approval of an ETH ETF has been less expected, leading to less extreme pre-positioning, the report says.

Upon the release of these reports, ETH futures open interest (OI) and funding rates were subdued compared to previous months. However, OI has started to increase, indicating rising anticipation of a potential ETF approval.

Net flows into Bitcoin ETFs have been a major driver of returns since their launch in January, explaining much of the cryptocurrency's performance. This trend is likely to continue with the introduction of ETH ETFs, indicating that overall crypto ETF flows will remain important for returns.

Reports indicate that robust conversations are ongoing behind the scenes between regulators and ETF providers, which include nine fund providers with applications pending at various stages. Past approvals for Bitcoin ETFs suggest that simultaneous launches for ETH ETFs are likely.

Historical data from Citi shows that net flows into spot Bitcoin ETFs materially influence cryptocurrency returns. For instance, net BTC ETF inflows totaled $12.9 billion through May 20, translating to a roughly 6% rally in Bitcoin per $1 billion of flow. Assuming similar market-cap-adjusted flows for ETH, estimated inflows could range between $3.8 billion to $4.5 billion, potentially driving ETH prices up by 23-28%.

Several factors could impact these estimates, including differing demand for ETH compared to BTC, rotation from BTC to ETH among existing ETF holders, outflows from existing ETH funds upon conversion, and rapid positioning build-up ahead of SEC approval.

In the long term, Citi analysts said that Bitcoin and Ethereum are expected to remain highly correlated, driven by macroeconomic factors. Despite differing on-chain activity and potential use-cases, such as Bitcoin's role as "digital gold" and Ethereum's smart contract functionality, sentiment, adoption, and further use-case development remain crucial for both cryptocurrencies.

"We expect the major tokens to remain highly correlated and continue to be driven by macro forces over the longer term," Citi memo concludes.

Original post:

Citi discusses Ethereum ETF: Buy the rumor, sell the fact? - Investing.com

Australian Academy of Science Boden Research Conference 2024: Protein Folding: Mechanisms, Health, and Machine … – Australian Academy of Science

Understanding how proteins fold is key to unlocking how cells function and how their structures are built. When proteins fold incorrectly, it can cause cells to malfunction, leading to diseases like Alzheimer's and Parkinson's. Delving into the complexities of protein folding not only enriches our fundamental understanding of biological processes but also paves the way for innovative therapies, and novel drug discoveries.

The 2024 Boden Research Conference aims to bring together a multidisciplinary community of experts to deepen our understanding of protein folding dynamics and propel therapeutic innovation. The conference will assess current knowledge, identify crucial gaps, and guide future research in protein folding and misfolding. The conference will also explore how machine learning can revolutionise the search for new treatments and better diagnosis of diseases.

Join us to discover how the smallest proteins can solve some of our biggest health challenges. Together, we can advance scientific understanding and develop new solutions to combat debilitating diseases.

Date: 25th -26th September, 2024

Time: 8:00am -17:00 pm. A conference dinner will be organised on day one (25th September, 2024) at 18:00 pm

Deadline: Deadline for conference registration is 23:59 13th September, 2024 (AEST) , and deadline for abstract submission is 23:59 15th July, 2024 (AEST).

Cost: Free

Venue:Holmes Building (A09), Science Rd, The University of Sydney, Camperdown NSW 2050, Australia

Program: TBA

Contact: Professor Ken-Tye Yong, The University of Sydney: ken.yong@sydney.edu.au; Dr Morning Liu, The University of Sydney: xiaochen.liu@sydney.edu.au

Read the original post:
Australian Academy of Science Boden Research Conference 2024: Protein Folding: Mechanisms, Health, and Machine ... - Australian Academy of Science

Ethereum ETF confirmed? VanEck spot Ether ETF listed by DTCC – Cointelegraph

Amid increasing speculation about the possible approval of a spot Ether exchange-traded fund (ETF) in the United States on May 23, global investment manager VanEcks ETF has been listed by the Depository Trust and Clearing Corporation (DTCC) under the ticker symbol ETHV.

The DTCC is an American financial market infrastructure provider that offers clearing, settlement and transaction reporting services to financial market players. A listing on DTCC is considered a crucial step before final approval from the U.S. Securities and Exchange Commission (SEC).

VanEcks ETF is currently designated inactive on the DTCC website, meaning it cannot be processed until it receives the necessary regulatory approvals. However, VanEck is not the first Ether (ETH) ETF listed by the DTCC. Franklin Templetonsspot ETH ETF was listed on the platform a month ago.

The DTCC said that the ETF list includes both active ETFs that may be processed by the DTCC and ETFs that are not yet active and, therefore, cannot be processed.

Another report suggested that SEC officials contacted Nasdaq, the Chicago Board Options Exchange and the New York Stock Exchange to update and change existing spot Ether ETF applications.

Related: Crypto insiders anxious and divided as spot Ether ETF decision date looms

The significant change in the SECs stance over the past week is speculated to be linked to the White House.

Crypto lawyer Jake Chervinsky noted in a post on X that policy is driven by politics, and for months, crypto has been winning the political battle. He also speculated that former president Donald Trumps endorsement of cryptocurrency compelled the administration of President Joe Biden to shift its policy.

May 23 is the final deadline for the SECs decision on the VanEck spot Ether ETF application. After months of speculation about a probable denial of spot ETH ETFs, the SEC took action earlier this week.

The SEC firstasked financial managers to amend and refile their 19b-4 filings on their proposed spot Ether ETFs. Some analysts saw the move as a positive sign, swinging the potential chance of approval to 75% from 25%.

Magazine: What do crypto market makers actually do? Liquidity, or manipulation

See original here:

Ethereum ETF confirmed? VanEck spot Ether ETF listed by DTCC - Cointelegraph